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Abstract: Diabetes mellitus is a group of chronic metabolic disorders characterized by 
hyperglycemia due to defects in insulin action and/or secretion. It is a worldwide problem 
which has led to illness and premature mortality for many people, and the number of 
diabetes cases has been rising sharply. Unluckily, many conventional antidiabetic agents 
either show limited efficacy or serious mechanism-based side effects. Marine macroalgae 
possess tremendous nutritional value and have been well-known to cure and prevent 
diabetes. An increased interest in various bioactive natural products from marine 
macroalgae, as a potential source of effective antidiabetic agents, has been observed in 
recent years. The effects of macroalgae may delay the development of diabetes and alter the 
metabolic abnormalities through various mechanisms of actions. This review provides an 
overview of marine macroalgae used to prevent and manage diabetes and explores the 
hypoglycemic properties of macroalgae-derived bioactive compounds such as polyphenol, 
bromophenols, sulfated polysaccharides, fucoidan, fucosterol, phlorotannins, carotenoid 
pigments and fucoxanthin with their probable mechanisms behind hypoglycemic activity. 
Keywords: Phaeophyta; rhodophyta; chlorophyta; bioactive compounds; hypoglycemic 
activity 
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1. Introduction 
Globalization, industrialization, and changes of human environment, behavior and lifestyle 
have led to increasing raising rates of both obesity and diabetes (Xiao & Högger, 2015). 
Diabetes mellitus, one of the most important global health problems, was estimated as the 
fifth leading cause of death globally (Roglic et al., 2005). The International Diabetes 
Federation (IDF) estimated that the number of diabetes cases is expected to grow to 438 
million globally in 2030 from 285 million people in 2009 (Atlas, 2009). It is a serious chronic 
disease characterized by hyperglycemia due to defects in insulin action, insulin secretion, or 
both of them (ADA, 2015). The main characteristic symptoms of diabetes are polyuria, 
polydipsia and polyphagia (ADA, 2005). The varying degrees of insulin resistance (Pontiroli, 
2004) and postprandial hyperglycemia play an important role in the development of type 2 
diabetes and related complications (Lee et al., 2012). An effective control of postprandial 
blood glucose level play key role in diabetes care which can improve the life quality of 
patients with type 2 diabetes. A number of pharmacological approaches have been used to 
control diabetes based on the different modes of action such as stimulation of insulin release, 
increase in glucose transport activity, inhibition of gluconeogenesis, and reducing absorption 
of glucose from the intestine (Thilagam, Parimaladevi, Kumarappan, & Mandal, 2013). 
Currently available therapies, including insulin and various oral antidiabetic agents, have 
been used as monotherapy or in combination to make a better glycemic regulation (Jung et al., 
2006). However, a number of those antidiabetic agents either have inadequate efficacy or 
serious mechanism-based side effects (Lee et al., 2014). Thus, the search and investigation 
for more effective and safer hypoglycemic agents from natural sources has continued to be an 
important issue (Vinayagam, Xiao, & Xu, 2017). 
  Owing to the rich biodiversity, the marine environment is a vast and relatively untapped 
source for new bioactive ingredients including polyunsaturated fatty acids, polyphenol, 
sterols, proteins, sulfated polysaccharides, antioxidants and pigments (Lee, Ko, Kang, Lee, & 
Jeon, 2016; Suleria, Gobe, Masci, & Osborne, 2016; Manikkam, Vasiljevic, Donkor, & 
Mathai, 2016; Saleh, Zhang, & Shen, 2016; Ruocco, Costantini, Guariniello, & Costantini, 
2016). Marine algae, the primary producers of all aquatic ecosystems, have served as 
important sources of bioactive natural substances including antidiabetic, antioxidant, 
 3 
antibacterial and antivirals agents (Choochote, Suklampoo, & Ochaikul, 2014; Zhao, Wu, 
Yang, Liu, & Huang, 2015). In particular, macroalgae are well-known healthy food with 
naturally rich in minerals and dietary fibers. Marine algae are consumed as a regular part of 
traditional diet in the Far East and Hawaiian Islands, Japan, Korea, and China. There are 
about 9,000 species macroalgae have been broadly classified into three categories according 
to their composition of pigments, i.e., Phaeophyta, Rhodophyta and Chlorophyta (or the 
brown, red, and green algae, respectively) (Khan et al., 2009). Diverse classes of unique 
metabolites have shown numerous biological activities and potential health benefits 
(Pangestuti & Kim, 2011), such as anticancer, antidiabetic, antihypertensive, 
antihyperlipidemic, antioxidant, anticoagulant, anti-inflammatory, anti-estrogenic, antiviral, 
antifungal, antibacterial, immunomodulatory, neuroprotective, and tissue healing properties in 
vivo (Mohamed, Hashim, & Rahman, 2012). With the identification of a large number of 
bioactive compounds from marine macroalgae, e.g., sulfated polysaccharides, phlorotannins 
and diterpenes, an increased level of attention has been given recently to study the potential 
applications of macroalgae and their components as functional ingredients for both human 
and animal health (Gupta & Abu-Ghannam, 2011). Functional ingredients of macroalgae 
have been found to possess antidiabetic properties and are typically used as food supplements 
(Pangestuti & Kim, 2011). This review paper pay close attention to the potential applications 
of marine macroalgae and/or macroalgae-derived bioactive compounds in diabetes 
management (Table 1), and also discusses their possible mechanisms of action. 
 
2. Phaeophyta (brown algae) 
2.1 Pelvetia Decne. & Thur. 
  Pelvetia is the genus of typical marine macroalgae, and comprises only four species. 
Pelvetia siliquosa  C.K.Tseng & C.F.Chang has been reported to self-grow on the craggy 
surfaces near the seashores of the southern area (Lee, 2003). Fucosterol (1), isolated from P. 
siliquosa, was shown to decrease serum glucose levels and to inhibit glycogen degradation in 
streptozotocin (STZ)-induced diabetic rats (Lee, Shin, Kim, & Lee, 2004). An extract from P. 
babingtonii (Harvey) de Toni (Fucaceae) exhibited potent α-glucosidase inhibitory activity 
and was effective for suppressing postprandial hyperglycemia (Ohta, Sasaki, Oohori, 
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Yoshikawa, & Kurihara, 2002). α-Glucosidase, an enzyme located in the brush-border 
membranes of human intestinal cells, is involved in carbohydrate metabolism and 
post-translational processing of glycoprptein (Li, Niu, Fan, Han, & Zhang, 2005). Similarly, 
α-amylase is a kind of main secretory products of the pancreas and salivary glands, 
constituting a family of endoamylases that plays a vital role in the digestive system and 
catalyses the initial step in hydrolysis of starch to a mixture of smaller oligosaccharides 
through the cleavage of α-D (1–4) glycosidic bonds (Kandra, 2003). α-Glucosidase and 
α-amylase have long been recognized as preferred drug targets for the modulation of 
postprandial hyperglycemia (Liu, Zhang, Wei, & Lin, 2011). Some marine macroalgae may 
be considered as natural inhibitors of α-glucosidase and α-amylase and be used as auxiliary 
hypoglycemic functional foods or drugs (Rengasamy, Kulkarni, Stirk, Van Staden, 2014). 
 
2.2 Ecklonia Hornemann 
  Several Ecklonia  species contain high levels of marine algal polyphenols (Yoon et al., 
2013). Polyphenols are one of the main classes of secondary metabolites found in terrestrial 
plants and marine macroalgae, but there are fundamental differences in the chemical 
structures of polyphenols found in both terrestrial and marine plants (Lee & Jeon, 2013). The 
methanolic extract of Ecklonia stolonifera  Okamura, a brown alga belonging to the algal 
family Lessoniaceae, has rich polyphenol content, which were shown strong inhibition effect 
on α-glucosidase activity in vitro as well as strong suppression of the increase in plasma 
glucose level and lipid metabolism in diabetic KK-Ay mice. The bioactive compounds were 
investigated to be phlorotannins (Gouveia et al., 2007; Iwai, 2008). Phlorotannins are 
polyphenols which widely occur in marine organisms, especially in brown macroalgae 
(Yotsu-Yamashita et al., 2013). A review have outlined various antidiabetic mechanisms 
associated with phlorotannins from brown algae ( Lee & Jeon, 2013). Phlorotannins from E. 
kurome Okamura showed inhibitory activities against carbohydrate-hydrolyzing enzymes in 
vitro and decreased postprandial blood glucose levels in vivo (Xu et al., 2012). Before that, 
Eisenia bicyclis (Kjellman) Setchell, Ecklonia stolonifera  and phlorotannins isolated from 
them, namely dieckol (2), eckol (3), 7-phloroeckol (4), and phlorofucofuroeckol-A (5) were 
shown to possess marked α-glucosidase and protein tyrosine phosphatase 1B (PTP1B) 
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inhibitory activities (Moon et al., 2011). Moreover, the insulin receptors are back to their 
original state via the activity of protein tyrosine phosphatases (PTPs) (Wälchli, Curchod, 
Gobert, Arkinstall, & van Huijsduijnen, 2000). PTP1B is a member of PTPs family that have 
been isolated and identified from mammalian cells, and it maintains the balance of protein 
tyrosine phosphorylation with protein tyrosine kinases (PTK). Cicirelli et al. (1990) reported 
that PTP1B was associated with insulin signal transduction for the first time. It has been 
established that PTP1B played an important role as a negative regulator of the insulin 
signalling pathway. Another study showed that a PTP1B knock-out mouse had increased 
insulin sensitivity (Elchebly et al., 1999). Several clinical studies have revealed that PTP1B is 
mainly responsible for dephosphorylation of the activated insulin receptor and thus down 
regulates insulin signaling, which can be an effective target for the therapy of type 2 diabetes 
(Zhang & Zhang, 2007).  
  Several known phloroglucinol derivatives isolated from E. cava  Kjellman, e.g., dieckol (2), 
7-phloroeckol (4), phlorofucofuroeckol-A (5), 6,6-bieckol (6), and fucodiphloroethol-G (7), 
possess significant inhibitory activities against α-amylase and α-glucosidase (Lee, Karadeniz, 
Kim, & Kim, 2009). Dieckol (2) not only inhibits the activities of α-glucosidase and 
α-amylase but also alleviates postprandial hyperglycemia and improve insulin sensitivity in 
vivo (Lee et al., 2010; Pontiroli, 2004). Dieckol (2) and the extract of E. cava can also offer 
the anti-diabetic effect through activating both adenosine 5’-monophosphate (AMP)-activated 
protein kinase (AMPK) and Akt kinase signal pathways (Kang et al., 2010; Kang et al., 2012). 
Adiponectin activates the downstream target AMPK which is a serine/threonine kinase that 
plays an important role in energy metabolism at both the cellular and whole-organism levels 
(Hardie, 2008; Padmalayam & Suto, 2013). AMPK controls whole-body glucose homeostasis 
by regulating metabolism in multiple peripheral tissues, and its activation induces the 
expression of PPARα and carnitine palmitoyltransferase I (CPT-1) that increase fatty acid 
oxidation and improve insulin sensitivity (Bijland, Mancini, & Salt, 2013; Long & Zierath, 
2006). Taking all these into account, it can be assumed that E. cava may have the potential as 
an AMPK activator to increase the expression of AMPK, thus controlling balance of blood 
glucose. However, there are only limited number of studies have investigated the role of 
macroalgae or macroalgae-derived compounds on activation of AMPK. 
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2.3 Laminaria J.V.Lamouroux 
  Laminaria japonica  J.E.Areschoug is one of the most important marine medicinal 
foodstuffs (Shirosaki & Koyama, 2011). Its rhizoid has long been applied as a traditional 
medicine for diabetes mellitus in China. Butyl-isobutyl-phthalate (8), extracted from L. 
japonica, exhibited hypoglycemic effect in vivo and non-competitive inhibition of 
α-glucosidase in vitro (Liu, Zhang, Qin, & Lin, 2011). The synthesized 
butyl-isobutyl-phthalate (8) bound with α-glucosidase and induced conformational changes of 
the enzyme, thus providing a potential to develop new α-glucosidase inhibitors (Liu, Zhang, 
Qiu, & Lin, 2011). However, further studies are needed to confirm those findings. Over the 
past decades, L. japonica  is a rich source of various functional compounds with diverse 
biological properties; among those, polysaccharides including alginate, fucoidan and 
laminaran are the main active components (Zha et al., 2012). Treatment with polysaccharides 
from L. japonica could significantly reduce fasting blood glucose and increase the levels of 
insulin and/or amylin in diabetic mice model (Li, Yu, Long, Guo, & Duan, 2012; Jia, Yang, 
Wang, Liu, & Xie, 2014). High fiber intake from dried whole seaweed supplements which 
consist of L. japonica  and Undaria pinnatifida  (48 g/day) could significantly reduce the 
concentrations of fasting and postprandial blood glucose and favorably altered lipid levels in 
20 obese diabetic individuals after a intervention of 4 weeks (Kim, Kim, Choi, & Lee, 2008). 
The above findings indicate that Laminaria  has rich antidiabetic potential, but further 
investigations are required to reveal the mechanisms associated with improving diabetic 
parameters, such as fasting and postprandial blood glucose concentrations. 
 
2.4 Sargassum C.Agardh 
  Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor 
superfamily of ligand-activated transcription factors (Michalik et al., 2006). There are three 
isotypes of PPAR, i.e. PPARα, PPARȕ/δ (PPARδ) and PPARȖ (Gervois, Fruchart & Staels, 
2007). Particularly, PPARα and PPARȖ are regarded as important pharmacological targets for 
the therapy of dyslipidemia and insulin-resistant diabetes, respectively (Pershadsingh, 2006). 
PPARȖ has been demonstrated to be the major functional receptor for the thiazolidinedione 
 7 
class of insulin-sensitizing drugs (Spiegelman, 1998). Activation of PPARα, which is 
predominantly expressed in the liver, could stimulate lipid consumption by enhancing the 
expression of fatty acid oxidation genes (Harrity et al., 2006). Combination the action of 
PPARα with PPARȖ (PPARα/Ȗ) are supposed to ameliorate both dyslipidemia and insulin 
sensitivity. Sargaquinoic acid (9) and sargahydroquinoic acid (10), extracted from Sargassum 
yezoense (Yamada) Yoshida & T.Konno, were identiﬁed as novel PPARα/Ȗ dual agonists 
(Kim, 2008). Sargaquinoic acid (9) and sargahydroquinoic acid (10) have beneﬁcial effects 
on glucose and lipid metabolism to improve metabolic disorders through dual activation of 
PPARα/Ȗ transcriptional activities without showing severe adverse effects as observed with 
previously identified PPAR agonists (e.g., body weight gain, heart failure, renal failure, 
urinary cancer and anemia) (Adeghate, Adem, Hasan, Tekes, & Kalasz, 2011; Kim, Lee, Bae, 
& Kee 2012). 
  Sargassum ringgoldianum Harvey and S. hemiphyllum (Turner) C.Agardh extracts have 
high concentration of polyphenols and fucoxanthin (11), respectively. Both of them possess 
α-glucosidase and α-amylase inhibitory activities as well as property of insulin secretion 
stimulation (Lee & Han, 2012; Hwang, Hung, Tsai, Chien, & Kong, 2014). Fucoidans are 
complex and heterogeneous sulphated polysaccharides that usually found in brown 
macroalgae, such as Fucus vesiculosus, Ecklonia kurome, and Undaria pinnatifida . 
Fucoidans extracted from S. wightii Greville ex J.Agardh could inhibit α-glucosidase (Vinoth 
et al., 2015). Thunberol (12), a sterol from the Chinese brown macroalga S. thunbergii 
(Mertens ex Roth) Kuntze, which is one of prolific seaweed growing widely along the coast 
of East China Sea, has been reported to inhibit the activity of PTP1B significantly with an 
IC50 value of 2.24 mg/mL (He, Yao, Liu, & Guo, 2014). An in vivo study revealed that a 
supplement of the S. coreanum J. Agardh extract could lower the blood glucose concentration 
by regulating the hepatic glucose metabolic enzyme activities and improving insulin 
resistance (Park, Nam, & Han, 2015). S. polycystum C. Agardh contains various nutrients and 
is traditionally used against several human diseases (Motshakeri et al., 2014). Both the 
alcohol and the water extracts of S. polycystum could obviously reduce the levels of blood 
glucose and hemoglobin A1c
 
(HbA1c) by increasing the response to insulin (Motshakeri, 
Ebrahimi, Goh, Matanjun, & Mohamed, 2013). HbA1c
 
was incorporated into the diagnostic 
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criteria for diabetes in updated 2010 guidelines of the American Diabetes Association (ADA, 
2010; WHO, 2011). The genus Sargassum has a wide range of active substances, but only 
limited studies have been performed on their antidiabetic activity.  
 
2.5 Others 
  Eisenia bicyclis (Kijillman) Setchell (Lessoniaceae) is a perennial and daily consumed 
edible brown alga that inhabits the middle Pacific coastlines of Korea and Japan. 
Phloroglucinol derivatives isolated from E. bicyclis exhibited great potential for the effective 
therapy of diabetic complications by inhibiting advanced glycation end-products (AGEs) 
formation and α-amylase activity (Okada, Ishimaru, Suzuki, & Okuyama, 2004). E. bicyclis 
and U. pinnatifida  (Harvey) Suringar high levels of fucoxanthin (11) and was shown to 
display potent inhibitory activity against AGEs formation and human recombinant aldose 
reductase (HRAR), rat lens aldose reductase (RLAR) and PTP1B activity (Ah et al., 2012). 
Phlorotannins extracted from Fucus vesiculosus L. (Fucaceae) inhibited the formation of 
AGEs mediated by glucose and methylglyoxal in a concentration-dependent manner (Liu & 
Gu, 2012). AGEs are the result of the Maillard reaction (nonenzymatic reaction), and may be 
formed as a result of normal metabolism and aging (Bakker et al., 2015). The accumulation 
of AGEs plays a pivotal role in the development and progression of diabetic complications 
(Rigalleau et al., 2015). Therefore, it may provide a potential means to control the 
development of diabetic complications by inhibiting AGEs formation.  
  Fucoxanthin (11), a marine carotenoid that is characteristically present in edible brown 
macroalgaes such as E. bicyclis (Arame), U. pinnatifida  (Wakame), was reported to improve 
insulin resistance and to ameliorate blood glucose levels (D'Orazio et al., 2012; Maeda & 
Dominguez, 2013). Insulin resistance is an important pathophysiological mechanism that 
predicts the progression to type 2 diabetes. Also, an in vivo study on high fat diet-induced 
obesity mice reflected that the fucoxanthin-rich diet could significantly suppress the body 
weight and white adipose tissue weight gain induced by the high fat diet and promoted 
mRNA expression of glucose transporter 4 (GLUT4) mRNA in skeletal muscle tissues 
(Maeda, Hosokawa, Sashima, Murakami-Funayama, & Miyashita, 2009). The glucose uptake 
in surrounding tissues is mediated by GLUT4 translocation which stimulated by Akt 
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(Ramachandran & Saravanan, 2015). Increasing the expression of GLUT4 could improve 
insulin sensitivity, thus reducing or preventing insulin resistance. Fucosterol (1) constitutes 
83–97% of the sterol content in brown macroalgae, and fucosterol (1) from Eisenia bicyclis 
and Ecklonia stolonifera  was found to be a promising candidate for the treatment of diabetes 
and diabetic complications through inhibiting HRAR, RLAR, PTP1B, α-glucosidase 
activities and AGEs formation (Jung et al., 2013; Sánchez-Machado, López-Hernández, 
Paseiro-Losada, & López-Cervantes, 2004). Fucoidans derived from the Sporophyll of 
Undaria pinnatifida were reported to substantially prevent hyperglycemia based on oral 
glucose tolerance tests in non-diabetic mice and significantly reduced the levels of blood 
glucose in diabetic mice (Kim, Yoon, & Lee, 2012). 
  Ascophyllum nodosum (L.) Le Jolis is a dominant rocky intertidal brown macroalga that 
grows abundantly in the northeastern coast of North America and the northwestern coast of 
Europe (Taylor, 1957). Water extracts of A. nodosum exhibited strong inhibitory activity 
against α-glucosidase and its phenolic compounds could be implicated to this activity 
(Apostolidis, Karayannakidis, Kwon, Chong, & Seeram, 2011). Several other studies have 
also demonstrated that polyphenol-enriched extracts from A. nodosum could inhibit 
α-glucosidase and α-amylase in vitro as well as have the potential to influence glycemic 
control in vivo (Apostolidis & Lee, 2010; Kim, Rioux, & Turgeon, 2014; Pantidos, Boath, 
Lund, Conner, & McDougall, 2014). Both Fucus vesiculosus and A. nodosum contain large 
amounts of fucoidan. Interestingly, fucoidan extracted from A. nodosum has shown stronger 
inhibitory activity of α-glucosidase than that of extracted from F. vesiculosus. In contrast, 
fucoidan from A. nodosum decreased α-amylase activity but fucoidan extracted from F. 
vesiculosus did not (Kim, Rioux, & Turgeon, 2014). This finding suggests that the ability of 
fucoidan for inhibition of α-glucosidase and α-amylase varies due to different the algae 
species and harvest period. Also, a double-blind experiment on healthy adults reflected that a 
single ingestion of dried whole seaweed extract from A. nodosum and F. vesiculosis favorably 
regulated insulin levels and sensitivity after a carbohydrate-rich meal but displayed no 
significant effect on postprandial glucose response (Paradis, Couture, & Lamarche, 2011). 
Their potential benefits in diabetes management should be further investigated. 
  Ishige okamurae Yendo is as an edible brown alga that grows on rocks in the upper and 
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middle intertidal zone on rough open coasts, and generally forms highly persistent 
populations in clear waters (Zou et al., 2008). Diphlorethohydroxycarmalol (13), a kind of 
phlorotannin, isolated from I. okamurae, displayed prominent inhibitory effect against 
α-amylase and α-glucosidase that might provide a good way to the regulation of carbon 
source, such as starch, during fermentation (Heo et al., 2009). The extracts of I. okamurae 
were also shown to have the abilities to lower the blood glucose levels by regulating the 
activities of hepatic glucose metabolic enzymes and improving insulin resistance in db/db 
mice (Min, Kim, Jeon, & Han, 2011). Octaphlorethol A (OPA, 14), a type of phlorotannin 
isolated from I. foliacea  has been shown to have the potential to improve type 2 diabetes for 
the first time (Lee, Ko, Kang, Lee, & Jeon, 2016). The OPA significantly improved fasting 
blood glucose level and impaired glucose tolerance in type 2 diabetic db/db mice with the 
mechanism of increasing in GLUT4-mediated glucose utilization via activation of AMPK in 
muscle. 
  Overall, there is a huge knowledge gap exists between Phaeophyta bioactive compounds 
and their roles in antidiabetic activities. Brown algae are rich in bioactive substances and 
many in vitro studies have demonstrated the hypoglycemic potential of many of those 
compounds. However, further research using in vivo studies should be conducted to offer a 
better understanding of the potential mechanisms of those compounds. 
 
3. Rhodophyta (red algae) 
  There are some red macroalgae that contain the bromophenols as algal enzyme inhibitors 
linked to diabetes mellitus (Table 2), such as the family Rhodomelaceae. Grateloupia 
elliptica Holmes contain two bromophenols such as 2,4,6-tribromophenol (15) and 2,4- 
dibromophenol (16) with α-glucosidase inhibitory activity (Kim, Nam, Kurihara, & Kim, 
2008; Kurihara, Mitani, Kawabata, & Takahashi, 1999b). Bromophenol extracts of G. 
elliptica can inhibit intestinal α-glucosidase and stimulated basal glucose uptake into 3T3-L1 
adipocytes (Kim, Nam, Kurihara, & Kim, 2008). Five highly brominated metabolites 
compounds (17–21; Table 2) isolated from a Chinese red alga Laurencia similis showed 
inhibitory activities against PTP1B (Qin et al., 2010). The compound named 
bis(2,3-dibromo-4,5-dihydroxybenzyl) ether (22) was purified from Odonthalia corymbifera  
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and Polyopes lancifolia possessed strong activity against α-glucosidases. Meanwhile, six 
bromophenols (23–28; Table 2) isolated from the Japanese red alga O. corymbifera also 
showed α-glucosidase inhibitory activity (Kurihara et al., 1999a). The two bromophenols 
such as 3-bromo-4,5-dihydroxybenzyl alcohol (29) and 3-bromo-4,5-dihydroxybenzyl methyl 
ether (30) from Polysiphonia morrowii displayed activity against α-glucosidase were 
identified for the first time from this species (Kurihara et al., 1999b). 
Bis-(2,3-dibromo-4,5-dihydroxyphenyl)-methane (31), isolated from red macroalgae 
Rhodomela confervoides (Hudson) P.C.Silva showed significant inhibition against PTP1B (Li, 
Guo, Su, Han, & Shi, 2008). What’s more, an in vivo study also demonstrated the 
antihyperglycemic effect of bromophenols (Shi et al., 2008). Four bromophenols namely 
3-bromo-4,5-bis(2,3-dibromo-4,5-dihydroxybenzyl)-1,2-benzene-diol (32), 
3,4-dibromo-5-(2-bromo-3,4-dihydroxy-6-(isopropoxymethyl)benzyl)benzene-1,2-diol (33), 
β,β′,γ,γ′-tetrabromo-4,4′,5,5′-tetra-hydroxydiphenyl methane (34) and 
β,β′,γ-tribromo-γ′,4,4′,5-tetrahydroxy-6′-ethyloxy-methyldiphenyl methane (35) are all 
bromophenols isolated from Rhodomela confervoides which have potent PTP1B inhibition 
(Jiang, Shi, Cui, & Guo, 2012; Shi et al., 2008; Shi, 2013). A series of bromophenols (36–43) 
purified from red alga Symphylocladia latiuscula  exhibited antidiabetic activity by inhibiting 
PTP1B. Otherwise, Kurihara et al. (1999a) have reported a bromophenol 
2,3,6-tribromo-4,5-dihydroxybenzyl alcohol (44) isolated from S. latiuscula  wtih 
α-glucosidase inhibition at a very low concentration. 
  Among the red seaweeds, Hypnea musciformis (Wulfen) J.V.Lamouroux extract diplayed 
antihyperglycemic, antioxidant and increased plasma insulin effects in diabetic animals 
(Anandakumar, Balamurugan, Rajadurai, & Vani, 2008). The edible red alga Gelidium 
amansii (J.V. Lamouroux) J.V. Lamouroux is mainly distributed in northeastern Taiwan. A 
mice study has shown that the plasma glucose significantly decreased in the group with oral 
treatment of G. amansii ethanol extract (Choi et al., 2015). The plasma glucose, triglyceride, 
and cholesterol concentrations in rats with diabetes fed the G. amansii diet for 11-week were 
lower than of in rats with diabetes fed the control diet (Yang, Yao, & Chiang, 2015). 
Gracilaria lemaneiformis (Bory) Greville occurs widely in the marine environment and 
belongs to the family Gracilariaceae (Rhodophyta), and the sulfated polysaccharide accounts 
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for about 30% of its dry weight (Yu, Wang, Chen, Zhang, & Long, 2006). A polysaccharide 
extracted from G. lemaneiformis inhibited α-glucosidase activity in vitro and the 
administration of polysaccharide (200 mg/kg body weight) for 21 days significantly 
decreased the blood glucose levels in diabetic mice (Liao et al., 2015). 
  The extract of Kappaphycus alvarezii (Doty) Doty ex Silva and the ethanol extract of fresh 
Eucheuma denticulatum (N. L. Burman) Collins & Hervey demonstrated the appreciable 
inhibitory activities towards α-amylase (Balasubramaniam et al., 2013; Nagarani & 
Kamaguru, 2013). K. alvarezii, K. striatus (F. Schmitz) Doty ex P.C.Silva and E. 
denticulatum are good sources of magnesium, which could provide 30%–90% of the daily 
demand per 100 g of dried macroalgae (Balasubramaniam et al., 2013). It is highly plausible 
that magnesium in red macroalgae is responsible for hypoglycaemic activity. Intracellular 
free magnesium levels have been found to be closely and inversely related to the level of the 
fasting blood glucose (Barbagallo et al., 2003). Magnesium , one of the most abundant ions 
present in living cells, plays a pivotal role in insulin homeostasis and glucose metabolism 
through multiple enzymatic reactions and its plasma concentration is remarkably constant in 
endocrine (Barbagallo et al., 2003). It was shown that serum magnesium levels declined with 
rise in HbA1c levels and with duration of type 2 diabetes (Ramadass, Basu, & Srinivasan, 
2015). Thus, increased consumption of magnesium-rich macroalgae may reduce the risk of 
type 2 diabetes. Gyeongshingangjeehwan 18 (GGEx18) is a kind of herbal drug composed of 
three medicinal plants: Rheum palmatum L. (Polygonaceae), Laminaria japonica  Aresch 
(Laminariaceae), and Ephedra sinica Stapf (Ephedraceae). A study revealed that GGEx18 
could significantly increase the expression of fatty acid oxidation genes, such as adiponectin, 
AMPKs, PPARα and its target enzymes, and CPT-1, in both mesenteric adipose tissues and 
3T3-L1 cells and normalized hyperglycemia and hyperinsulinemia in obese mice, thus reduce 
the blood glucose levels (Oh et al., 2014). Porphyran from the red alga Porphyra yezoensis 
Ueda is a water-soluble dietary fiber. A study revealed that dietary porphyran should increase 
adiponectin levels thus improving glucose metabolism in diabetes (Kitano et al., 2012). 
Adiponectin is an adipokine that exerts a strong insulin-sensitizing effect by binding to its 
receptors like AdipoR1 and AdipoR2, resulting in activation of AMPK, PPARα, and 
presumably some other unknown signaling pathways (Kadowaki et al., 2006). Therefore, the 
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adiponectin gene appears to be a promising candidate susceptibility gene for type 2 diabetes. 
  Most of the seaweeds contain high contents of soluble dietary fibers such as carrageenan, 
agar, and alginates, which could passively retard digestion and glucose absorption. The 
beneficial effects of Rhodophyta species on the prevention and management of 
diabetes-related risks have clearly been indicated from in vitro and in vivo animal models. 
Nevertheless, deep and systematic studies, especiallyfocusing on mechanisms of action, are 
still needed. Studies on Rhodophyta sp. and Rhodophyta-derived compounds with 
hypoglycemic activity are still insufficient. Thus, further research in this area is imperative to 
look for more species with hypoglycemic activity and to provide strong evidence of potential 
beneficial effects of hypoglycemic functional foods or drugs from macroalgae. 
 
4. Chlorophyta (green algae) 
  Ulva lactuca L. is a common green macroalga in the division Chlorophyta and found 
widespread in China (Tian, Yin, Zeng, Zhu, & Chen, 2015). Polysaccharides isolated from U. 
lactuca could significantly decrease the blood glucose by their potential inhibitory effect on 
key enzymes closely related to starch digestion and absorption in both plasma and small 
intestine (Belhadj, Hentati, Elfeki, & Hamden, 2013). The Ulva rigida  ethanolic extract 
decreased blood glucose concentrations and micronuclei frequency in diabetic rats (Celikler 
et al., 2009; Tas, Celikler, Ziyanok‐ Ayvalik, Sarandol, & Dirican, 2011). Oxidative stress is 
an important factor which responsible for complications in diabetes (Sukmawati et al., 2015). 
Diabetes is generally accompanied by increased production of the molecules of reactive 
oxygen species and/or impaired antioxidant defense systems, which lead to oxidative damage 
to biomolecules. Exposure of the genetic material to reactive oxygen species could cause 
DNA damage (Evans, Dizdaroglu, & Cooke, 2004). There are some reports on the 
antidiabetic activities of other Ulva  species, such as U. fasciata  Delile, have the abilities to 
reduce blood glucose level, and restore hepatic glycogen content, carbohydrate metablic 
enzymes like hexokinase, glusokinase and glucose 6-phoshatase activity in vivo (Abirami & 
Kowsalya, 2013). Protein kinase C is a family of protein kinase enzymes that are involved in 
controlling the intracellular signal transduction (Anderson, Mcgill, & Tuttle, 2007). The 
activation of protein kinase C may occur in the organs susceptible to developing diabetic 
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complications, especially diabetic nephropathy (Kizub, Klymenko, & Soloviev, 2014).  
   
5. Potential anti-diabetic natural products from marine algae 
The WHO Expert Committee recommended that medicinal plants used in the treatment of 
diabetes be further investigated as they are frequently considered to be lesser or no adverse 
effects (Halberstein, 2005). Search for more safe and effective bioactive agents has continued 
to be an important target in the field of diabetic research. Less than 1% of the estimated 
250,000 higher plants have been screened pharmacologically and very few in regard to 
diabetes (Arumugam, Manjula, & Paari, 2013). The ethnobotanical information reports state 
that about 800 plants and their active extracts which may possess hypoglycemic potential 
have been found. In which, about 200 pure bioactive compounds have been identified and 
reported for their potential anti-diabetic effects (Alarcon-Aguilara et al., 1998; Suksomboon, 
Poolsup, Boonkaew, & Suthisisang, 2011). These natural phytoconstituents showing 
anti-diabetic efficacy include flavonoids, alkaloids, tannins, saponins, terpenoids, phenolics, 
glycosides, steroids, chalcones, carotenoids, peptides, lipids, glycopeptides, iridoids, ursolic 
acid and imidazoline (Wu, Hsieh, Lin, & Yen, 2013). The bioactive compounds are found in 
many fruits, vegetables, herbs, tea, soy and beverage products, and mostly together 
responsible for efficacy (Edirisinghe & Burton-Freeman, 2016). 
So far, approximately 22,000 natural products of marine organisms have been discovered  
whereas 131,000 terrestrial natural products exist (Blunt, Copp, Munro, Northcote, & Prinsep, 
2011). According to a recent study, an estimate of 72,500 algal species has been described 
throughout the world, where as most of them are marine (Guiry, 2012). To survive in various 
diverse and extreme environments, marine macroalgae produce a variety of natural bioactive 
compounds and metabolites (Wang, Li, Lee, & Chang, 2017). Polyphenols and 
polysaccharides from marine macroalgae particularly showed very significant antidiabetic 
potential against pharmacological experimental systems via interfering in carbohydrate 
metabolism. Marine algae-derived functional metabolites indicate structural and functional 
diversity from their terrestrial counter-part due to the differences in their metabolic pathways 
(Guven, Percot, & Sezik, 2010). Algal polyphenols are derived from polymerized 
phloroglucinol units, whereas polyphenols from terrestrial plants are derived from gallic and 
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ellagic acids. They are termed as phlorotannins and biosynthesized via acetate malonate 
pathway (Arnold & Targett, 2002). At all events, the most active candidates will be 
determined through measuring different biochemical parameters such as fasting blood 
glucose, insulin, glycosylated hemoglobin, lipid profile, serum urea and creatinine, plasma 
alanine and aspartate transaminases, or microscopical examinations of pancreatic sections. 
 
6. Conclusion 
  Marine macroalgae and functional ingredients derived from them have increasingly been 
playing a more and more important role in body health and human nutrition. Bioactive 
constituents from marine macroalgae and their byproducts, like phlorotannins, fucosterol, and 
carotenoid pigments including fucoxanthin can be used indirectly as functional ingredients 
for the reduction of incidences of many chronic diseases in humans (Li & Kim, 2011). 
Diabetes mellitus has been considered to be one of the most important global health problems 
and there are many potential ways for macroalgae and macroalgae-derived bioactive 
compounds to treat diabetes, including α-glucosidase and α-amylase inhibition, activation of 
both AMPK and Akt signal pathways as well as HRAR, RLAR, PTP1B activities and AGE 
formation inhibition etc. Marine macroalgae are usually perceived as less toxic with fewer 
side-effects compared with those synthetic antidiabetic drugs. Current understanding on the 
antidiabetic effects of marine macroalgae and their compounds is almost based on the data 
available from in vitro and in vivo animal studies, however, these data cannot be extrapolated 
into the human setting without reliable human clinical data. Further investigations are 
imperative to unveil many more macroalgae and their components, which may have 
antidiabetic potentials. It is also important to look in to the possible mechanisms of 
antidiabetic actions of these marine macroalgae and their compounds. These antidiabetic 
therapeutics from natural source are valuable lead compounds, However, they seldom can be 
for direct clinical use and structural modifications are necessary. As a primary requirement 
for drug development, the future potential of algal natural products used in diabetes will be 
based on the modification of structures of biologically active compounds. In addition, 
original alga-derived natural products is unfeasible to meet market demands and alternative 
resupply approaches are being developed based on biotechnological production or chemical 
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semi-synthesis from naturally occurring precursors. Industry-scale production of complex 
natural products can be harvested in the future align with the progress of the knowledge of 
plant biosynthetic pathways and the development of more efficient genetic engineering 
strategies and tools. It is of immense importance to gain idea on enhancement of 
bioavailability and intrinsic potency with structure–activity relationship studies of algal 
bioactive compounds for the treatment of diabetes. Moreover, clinical research is needed to 
confirm the real efficacy of marine macroalgae to aid in diabetes prevention and 
management . Pharmacists should encourage patients to seek advice about the addition of 
these antidiabetic therapeutics for the treatment of diabetes. More research is needed to 
identify and quantify the phytochemical compounds on diabetes, as well as the combination 
therapy of algal natural products with the synthetic drugs. It is reasonable to state that marine 
macroalgae seem to have great developing potential in medicinal preparation to be 
sustainable nutraceutical or functional foods for complementary and alternative diabetes 
therapy. 
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Fig. 1 Chemical structures of bioactive compounds from marine macroalgae (references seen in Table 1 
and Table 2) 
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Table 1 Preclinical trials with marine macroalgae 
Macroalgae Major compound Effects References 
Pelvetia siliquosa Fucosterol (1) Inhibition of blood glucose level and glycogen degradation Lee et al., 2004 
Pelvetia babingtonii Methanol extract α-Glucosidase inhibition and suppression of postprandial hyperglycemia Ohta et al., 2002 
Ecklonia stolonifera Polyphenols α-Glucosidase inhibition; Suppression of the increase in plasma glucose Gouveia et al., 2007; Iwai, 2008 
Phlorotannins PTP1B and α-glucosidase inhibition Moon et al., 2011 
Fucosterol (1) RLAR, HRAR, PTP1B, α-glucosidase activities and AGE formation inhibition Jung et al., 2013 
Eisenia bicyclis 
Ecklonia stolonifera 
Dieckol (2) 
Eckol (3) 
7-Phloroeckol (4) 
Phlorofucofuroeckol-A (5) 
α-Glucosidase and PTP1B Moon et al., 2011 
Ecklonia cava Dieckol (2) 
7-Phloroeckol (4) 
Phlorofucofuroeckol-A (5) 
6,6-Bieckol (6) 
Fucodiphloroethol-G (7) 
Activation of both AMPK and Akt signal pathways; Improvement of insulin 
sensitivity; α-Glucosidase and α-amylase inhibition 
Kang et al., 2012 
Pontiroli, 2004 
Lee et al., 2010 
Ecklonia kurome Phlorotannins α-Amylase inhibition; Amelioration of hyperinsulinemia Xu et al., 2012 
Laminaria japonica Polysaccharides Reduced fasting blood glucose; Increased the levels of insulin and amylin Li et al., 2012; Jia et al., 2014 
Butyl-isobutyl-phthalate (8) α-Glucosidase inhibition Bu et al. 2010 
Sargassum ringgoldianum Polyphenol α-Amylase and α-glucosidase inhibition Lee et al., 2012 
Sargassum yezoense Sargaquinoic acid (9) 
Sargahydroquinoic acid (10) 
Enhances the transcriptional activities of PPARα and PPARȖ Kim et al., 2012 
Amelioration of insulin resistance Kim, 2008 
Sargassum wightii Fucoidan α-D-glucosidase inhibition Vinoth et al., 2015 
Sargassum polycystum Extract Increasing insulin sensitivity Motshakeri et al., 2013 
Sargassum hemiphyllum Fucoxanthin (11) α-Amylase, α-glucosidase inhibition and insulin release enhancement  Hwang et al., 2014 
Sargassum thunbergii Thunberol (12) PTP1B inhibition He, Yao, Liu, & Guo, 2014 
Sargassum coreanum Extract Alteration of the hepatic glucose metabolic enzyme activities and improvement of Park, Nam, & Han, 2015 
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insulin resistance  
Undaria pinnatifida Fucoxanthin (11) HRAR, RLAR, PTP1B inhibition, and AGE formation Ah et al., 2012 
Improve insulin signaling Maeda et al., 2013 
Eisenia bicyclis Phlorotannins Inhibition of AGEs and α-amylase Okada et al., 2004 
Fucoxanthin (11) Inhibition of RLAR, HRAR, PTP1B activities and AGE formation Ah et al., 2012 
Fucosterol (1) Inhibition of RLAR, HRAR, PTP1B, α-glucosidase activities and AGE formation Jung et al., 2013 
Ascophyllum nodosum Phlorotannins  
Fucoidan 
α-Amylase and α-glucosidase inhibition Apostolidis et al., 2011; Kim et 
al., 2014; Pantidos et al., 2014 
Ishige okamurae Diphlorethohydroxycarmalol (13) α-Amylase and α-glucosidase inhibition Heo et al., 2009 
Ishige okamurae Extract Altering the hepatic glucose metabolic enzyme activities and improves insulin 
resistance. 
Min et al., 2011 
Ishige foliacea  Octaphlorethol A (14) Increasing in GLUT4-mediated glucose utilization via activation of AMPK in 
muscle. 
Lee, Ko, Kang, Lee, & Jeon, 
2016 
Kappaphycus alvarezii 
Eucheuma denticulatum 
Extract Inhibitory activity towards α-amylase Nagarani & Kamaguru 2013; 
Balasubramaniam et al., 2013 
Gracilaria lemaneiformis Polysaccharide Inhibitory to the α-glucosidase activity; decrease in blood glucose levels Liao et al., 2015 
Gelidium amansiithe  Ethanol extract Plasma glucose significantly decreased Choi et al., 2015 
Porphyra yezoensis Porphyran Increasing adiponectin levels  Kitano et al., 2012 
Ulva rigida Ethanolic extract Regeneration of ȕ-cells and/or potentiating the insulin release Celikler et al., 2009; Tas et al., 
2011 
Ulva fasciata Sulfated polysaccharides Reduce blood glucose level, and restore hepatic glycogen content and carbohydrate 
metablic enzymes 
Abirami & Kowsalya, 2013  
Ulva lactuca Polysaccharides α-Amylase, maltase and sucrase inhibition; Delay glucose absorption Belhadj et al., 2013 
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Table 2 The bromophenols from red algae as algal enzyme inhibitors linked to diabetes mellitus 
Red algae Bromophenols Major activity References 
Grateloupia elliptica 2,4,6-Tribromophenol (15) α-Glucosidase inhibition Kim, Nam, Kurihara, & Kim, 2008 
2,4-Dibromophenol (16)   
Laurencia similis γ′,5′,6′,6-Tetrabromo-2,4-dimethyldiphenyl ether (17) PTP1B inhibition Qin et al., 2010 
1,2,5-Tribromo-3-bromoamino-7-bromomethylnaphthalene (18)   
2,5,8-Tribromo-3-bromoamino-7-bromomethylnaphthalene (19)   
2,5,6-Tribromo-3-bromoamino-7-bromomethylnaphthalene (20)   
β′,5′,6′,5,6-Pentabromo-γ′,4′,γ,4-tetramethoxybenzo-phenone (21)   
Bis-(2,3-dibromo-4,5-dihydroxybenzyl) ether (22)   
Odonthalia corymbifera Bis-(2,3-dibromo-4,5-dihydroxybenzyl) ether (22) α-Glucosidase inhibition Kurihara et al., 1999a 
2,3-Dibromo-4,5-dihydroxybenzyl alcohol (23)   
2,3-Dibromo-4,5-dimethoxybenzyl methyl ether (24)   
4-Bromo-2,3-dihydroxy-6-hydroxymethylphenyl 
2,5-dibromo-6-hydroxy-3-hydroxymethylphenyl ether (25) 
  
4-Bromo-2,3-dimethoxy-6-methoxymethylphenyl 
2,5-dibromo-6-methoxy-3-methoxymethylphenyl ether (26) 
  
4-Bromo-2,3-dimethoxy-6-methoxymethylphenyl 
2,5-dibromo-6-methoxy-3-methoxymethylphenyl ether (27) 
  
3-Bromo-4,5-dimethoxybenzyl methyl ether (28)   
Polyopes lancifolia Bis-(2,3-dibromo-4,5-dihydroxybenzyl) ether (22) α-Glucosidase inhibition  Kim, Kurihara, & Kim, 2010  
Polysiphonia morrowii 3-Bromo-4,5-dihydroxybenzyl alcohol (29) α-Glucosidase inhibition  Kurihara et al., 1999b 
3-Bromo-4,5-dihydroxybenzyl methyl ether (30)   
Rhodomela confervoides Bis-(2,3-dibromo-4,5-dihydroxybenzyl) methane (31) Potent PTP1B inhibition  Li et al., 2008;  
 3-Bromo-4,5-bis(2,3-dibromo-4,5-dihydroxybenzyl)-1,2-benzene-diol (32)  Jiang et al., 2012; Shi 2013 
3,4-Dibromo-5-(2-bromo-3,4-dihydroxy-6-(isopropoxymethyl)benzyl)benzene-1,2-diol (33)   
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β,β′,γ,γ′-Tetrabromo-4,4′,5,5′-tetra-hydroxydiphenyl methane (34)  Shi et al., 2008 
β,β′,γ-Tribromo-γ′,4,4′,5-tetrahydroxy-6′-ethyloxy-methyldiphenyl methane (35)   
Symphylocladia latiuscula 2,3-Dibromo-4,5-dihydroxybenzyl methyl ether (36) PTP1B inhibition Liu et al., 2011 
3,5-Dibromo-4-hydroxybenzoic acid (37)   
2,3,6-Tribromo-4,5-dihydroxymethylbenzene (38)   
2,3,6-Tribromo-4,5-dihydroxybenzaldehyde (39)   
2,3,6-Tribromo-4,5-dihydroxybenzyl methyl ether (40)   
Bis-(2,3,6-tribromo-4,5-dihydroxyphenyl) methane (41)   
1,2-Bis-(2,3,6-tribromo-4,5-dihydroxyphenyl)-ethane (42)   
1-(2,3,6-Tribromo-4,5-dihydroxybenzyl)-pyrrolidin-2-one (43)   
2,3,6-Tribromo-4,5-dihydroxybenzyl alcohol (44) α-Glucosidase inhibition  Kurihara et al., 1999a 
 
 
